Inozyme Price To Free Cash Flows Ratio from 2010 to 2024

INZY Stock  USD 2.71  0.01  0.37%   
Inozyme Pharma Price To Free Cash Flows Ratio yearly trend continues to be fairly stable with very little volatility. Price To Free Cash Flows Ratio will likely drop to -3.27 in 2024. During the period from 2010 to 2024, Inozyme Pharma Price To Free Cash Flows Ratio regression line of annual values had significance of  0.000024 and arithmetic mean of (18.94). View All Fundamentals
 
Price To Free Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
(3.11)
Current Value
(3.27)
Quarterly Volatility
11.25112559
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.3 M, Interest Income of 4.3 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.65. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.
  
Check out the analysis of Inozyme Pharma Correlation against competitors.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Price To Free Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Free Cash Flows Ratio of Inozyme Pharma over the last few years. It is Inozyme Pharma's Price To Free Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.
Price To Free Cash Flows Ratio10 Years Trend
Slightly volatile
   Price To Free Cash Flows Ratio   
       Timeline  

Inozyme Price To Free Cash Flows Ratio Regression Statistics

Arithmetic Mean(18.94)
Coefficient Of Variation(59.41)
Mean Deviation10.13
Median(27.38)
Standard Deviation11.25
Sample Variance126.59
Range26.7011
R-Value0.87
Mean Square Error32.94
R-Squared0.76
Significance0.000024
Slope2.19
Total Sum of Squares1,772

Inozyme Price To Free Cash Flows Ratio History

2024 -3.27
2023 -3.11
2022 -0.68
2021 -3.31
2020 -13.21
2019 -14.03

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Price To Free Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Free Cash Flows Ratio(3.11)(3.27)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.